(Q54514577)

30 May 2018

title

Good antimicrobial prescribing. Clinical uses of cephalosporins (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6124680

9 August 2023

author name string

H. C. Neu

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6124680

9 August 2023

language of work or name

English

0 references

publication date

1 July 1982

1 reference

30 May 2018

31 July 1982

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6124680

full work available at URL

9 August 2023

https://api.elsevier.com/content/article/PII:S0140673682903336?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(82)90333-6

https://api.elsevier.com/content/article/PII:S0140673682903336?httpAccept=text/plain

9 August 2023

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(82)90333-6

9 August 2023

1 reference

30 May 2018

volume

2

1 reference

30 May 2018

issue

8292

1 reference

30 May 2018

page(s)

252-255

1 reference

30 May 2018

The place of cephalosporins in antibacterial treatment of infectious diseases

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990333-6

7 January 2021

Gram-Negative Rod Bacteremia: Microbiologic, Immunologic, and Therapeutic Considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990333-6

7 January 2021

Clinical evaluation of moxalactam

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990333-6

7 January 2021

Use of cefotaxime, a β-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990333-6

7 January 2021

Moxalactam therapy for bacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990333-6

7 January 2021

Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990333-6

7 January 2021

Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990333-6

7 January 2021

A randomized comparison of cefoxitin with or without amikacin and clindamycin plus amikacin in surgical sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990333-6

7 January 2021

Therapy of obstetrical infections with moxalactam

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990333-6

7 January 2021

Moxalactam: Clinical Summary of Efficacy and Safety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990333-6

7 January 2021

Past and current roles for cephalosporin antibiotics in treatment of meningitis. Emphasis on use in gram-negative bacillary meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990333-6

7 January 2021

Treatment of purulent meningitis with a new cephalosporin-Rocephin (Ro 13-9904). Clinical, bacteriological and pharmacological observations in 24 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990333-6

7 January 2021

Cefoxitin: An Overview of Clinical Studies in the United States

series ordinal

6

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(82)90333-6

9 August 2023

Identifiers

1 reference

30 May 2018

1 reference

30 May 2018